ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Multiple Myeloma

Multiple Myeloma

Socioeconomic factors affected the care and survival of younger patients with multiple myeloma, but race/ethnicity itself did not influence survival.

Results of important studies addressing the optimal consolidation regimen and choice and duration of maintenance therapy are eagerly awaited, but it is evident that ASCT is imperative in the treatment of younger patients with multiple myeloma.

Myeloma is clearly not one disease but several. In terms of treatment choices, it is increasingly evident that one size of treatment does not fit all. Moreover, as therapy is tailored to each individual patient, with the ability to mobilize and collect stem cells and retain them after successful induction/remission therapy, younger patients have choices.

Treatment with carfilzomib, lenalidomide, and dexamethasone improved the poor prognosis associated with high-risk cytogenetic abnormalities of multiple myeloma.

A new study found that monitoring of minimal residual disease in a group of elderly patients with multiple myeloma proved to have important prognostic value, regardless of patient age or cytogenetic risk.

Continuous lenalidomide plus low-dose dexamethasone reduced the risk for progression in untreated multiple myeloma patients who were ineligible for stem cell transplantation.

In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.

Pages

Subscribe to Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.